SYNTARA LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.017 AUD | -5.56% |
|
+6.25% | -15.00% |
| Apr. 30 | Transcript : Syntara Limited, Q3 2024 Earnings Call, Apr 30, 2024 | |
| Apr. 10 | Syntara Reaches 50% Recruitment in Phase 2 Trial for Bone Marrow Cancer Treatment | MT |
Presenter SpeechSamantha Freidin (Attendees)Good morning, everyone. So just on 11:00, we'll ge...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Syntara Limited, formerly Pharmaxis Ltd, is an Australia-based clinical-stage drug development company with a focus on blood-related cancers. The Companyâs highly productive drug discovery engine is driven by its expertise in amine oxidase inhibitors. Its lead candidate, PXS-5505, is used for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The Company is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its PXS-4728 is a SSAO/MAOB inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinsonâs by reducing neuroinflammation. The Companyâs other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis, and cardiac fibrosis. It has developed two respiratory products: Bronchitol, for cystic fibrosis, and Aridol, a lung function test.
Sector
Pharmaceuticals
Calendar
2024-08-13
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -15.00% | 14.36M | |
| +32.36% | 709B | |
| +30.77% | 595B | |
| -1.60% | 367B | |
| +20.07% | 334B | |
| +6.04% | 289B | |
| +14.77% | 239B | |
| +9.13% | 211B | |
| -3.97% | 203B | |
| +9.27% | 171B |
- Stock Market
- Equities
- SNT Stock
- News Syntara Limited
- Transcript : Pharmaxis Ltd, Q2 2022 Earnings Call, Jan 31, 2022